Pegcetacoplan for 52 Weeks Maintains Proteinuria Reduction Regardless of Immunosuppressant Use or Nephrotic-Range Proteinuria at Baseline: VALIANT Subgroup Analysis

Carla Nester; Andrew S. Bomback; María Gema Ariceta Iraola; Yahsou Delmas; Bradley P. Dixon; Daniel P. Gale; Larry A. Greenbaum; Seung Hyeok Han; Nicole M. Isbel; Christoph Licht; Antonio Mastrangelo; Masashi Mizuno; Maria Izabel Neves de Holanda; Matthew C. Pickering; Giuseppe Remuzzi; Nicole C. A. J. van de Kar; Marina Vivarelli; Patrick D. Walker; Dean Wallace; Daniel Zecher; Moglie Le Quintrec; Yael Borovitz; Nabil Melhem; Fádi Fakhouri

doi:10.1681/asn.20256pz3xtrx

Related publications

Article2025

Pegcetacoplan for 52 Weeks Results in Sustained Proteinuria Reduction to Remission (≤0.5 g/g) and Normalization (≤0.2 g/g): Phase 3 VALIANT Trial

Carla Nester, Fádi Fakhouri, Daniel P. Gale, Andrew S. Bomback, Christoph Licht, Giuseppe Remuzzi, Nicole C. A. J. van de Kar, K. Gordon, Anwesha Mukherjee, Johan Szamosi, Lucía Quintana, Matthew C. Pickering

Article2025

#3265 Pegcetacoplan treatment effect in patients with nephrotic range proteinuria: results from the VALIANT Phase 3 study in patients with C3G or primary (idiopathic) IC-MPGN

Marina Vivarelli, Andrew S. Bomback, Gema Ariceta, Antonio Mastrangelo, Carla Nester, Giuseppe Remuzzi, Nicole C. A. J. van de Kar, Zhongshen Wang, Johan Szamosi, Dima Decker, Lenny Gallardo, Fádi Fakhouri

Article2025

VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN

Carla Nester, Andrew S. Bomback, Gema Ariceta, Yahsou Delmas, Bradley P. Dixon, Daniel P. Gale, Larry A. Greenbaum, Seung Hyeok Han, Nicole M. Isbel, Christoph Licht, Antonio Mastrangelo, Masashi Mizuno, Maria Izabel Neves de Holanda, Matthew C. Pickering, Giuseppe Remuzzi, Nicole C. A. J. van de Kar, Marina Vivarelli, Patrick D. Walker, Dean Wallace, Daniel Zecher,

Article2017

Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics: The FINGER trial

Anna Rosenberg, Tiia Ngandu, Minna Rusanen, Riitta Antikaínen, Lars Bäckman, Satu Havulinna, Tuomo Hänninen, Tiina Laatikainen, Jenni Lehtisalo, Esko Levälahti, Jaana Lindström, Teemu Paajanen, Markku Peltonen, Hilkka Soininen, Anna Stigsdotter‐Neely, Timo Strandberg, Jaakko Tuomilehto, Alina Solomon, Miia Kivipelto

Alzheimer s & Dementia

Article2018

Subgroup Analysis of Patients with Biochemical or Symptomatic Relapse at the Time of Enrollment in the Endeavor Study

Philippe Moreau, David S. Siegel, Hartmut Goldschmidt, Rubén Niesvizky, Sara Bringhen, Robert Z. Orlowski, Julie Blædel, Zhao Yang, Meletios A Dimopoulos

Pegcetacoplan for 52 Weeks Maintains Proteinuria Reduction Regardless of Immunosuppressant Use or Nephrotic-Range Proteinuria at Baseline: VALIANT Subgroup Analysis

Discussion(0)

Related publications

Pegcetacoplan for 52 Weeks Results in Sustained Proteinuria Reduction to Remission (≤0.5 g/g) and Normalization (≤0.2 g/g): Phase 3 VALIANT Trial

#3265 Pegcetacoplan treatment effect in patients with nephrotic range proteinuria: results from the VALIANT Phase 3 study in patients with C3G or primary (idiopathic) IC-MPGN

VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN

Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics: The FINGER trial

Subgroup Analysis of Patients with Biochemical or Symptomatic Relapse at the Time of Enrollment in the Endeavor Study